Lys380

Site Information
LPTNDkkkWARPPIs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 15384585

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:	lymphoma ( 4 ) , B cell lymphoma ( 4 )
Relevant cell line - cell type - tissue:	HEK293T (epithelial) ( 3 ) , HEp-2 (squamous) ( 1 ) , Jurkat (T lymphocyte) ( 2 ) , MV4-11 (macrophage) ( 3 ) , NCCIT (epithelial) ( 5 ) , SU-DHL-4 (B lymphocyte) ( 4 )

References
1	Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640 29967540 Curated Info
2	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
3	Wagner SA, et al. (2011) A Proteome-wide, Quantitative Survey of In Vivo Ubiquitylation Sites Reveals Widespread Regulatory Roles. Mol Cell Proteomics 10, M111.013284 21890473 Curated Info
4	Guo A (2010) CST Curation Set: 9188; Year: 2010; Biosample/Treatment: cell line, SU-DHL-4/untreated; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
5	Zhou J (2010) CST Curation Set: 9131; Year: 2010; Biosample/Treatment: cell line, NCCIT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info